Aisling Capital invests in Eidos Therapeutics, Inc.

On January 1, 2018, Aisling Capital invested in Eidos Therapeutics, Inc., a life science company in California, United States.

Deal at a glance

AnnouncedJanuary 1, 2018 TypePIPE TargetEidos Therapeutics, Inc. Buyer Aisling Capital SectorLife Science LocationCalifornia, United States ValueNot disclosed

Target company

Eidos Therapeutics, Inc.

California, United States

Life Sciencesector

2006founded

Activestatus

View the company profile →

Buyer

Aisling Capital

Private equity firm · 88 deals on record

32nd transaction in life science
41st transaction in United States

88deals, all time

65in this sector

2020latest

Members only

Contact details at the buyers and sellers

The full deal history of every party

Co-investors and the other advisors on this deal

Deal value and revenue or EBITDA multiples

Related deals

Orbus Therapeutics, Inc.Same sector and country · Oct 2026

ArtesRx LLCSame sector and country · Aug 2026

Firefly Bio, Inc.Same sector and country · Jul 2026

Questions about this deal

Who acquired Eidos Therapeutics, Inc.?Aisling Capital invested in Eidos Therapeutics, Inc. on January 1, 2018.

What type of deal was it?It was a pipe in the life science sector in 2018.

See the full picture on AcquityDataContacts, full deal histories, co-investors and deal values. Free for a day with your Google account, no card needed.

Try it free

Data updated daily on AcquityData (Acquity Data).